Impact BioMedical (IBO) Q2 2025 earnings summary

Executive summary

• Net loss for Q2 2025 was $14.4M, a 1,524% increase year-over-year, driven by higher headcount, insurance, professional fees, and a significant fair value adjustment to related party debt.

• Revenue remained minimal at $7,000 for the quarter, with biotech retail sales as the sole source.

• The company completed an IPO in September 2024, raising $3.7M net and listing on NYSE American under ticker IBO.

• A merger and share exchange agreement with Dr Ashleys Limited is anticipated to close in Q4 2025.

Financial highlights

• Total revenue for Q2 2025 was $7,000, unchanged from the prior year.

• Operating loss for Q2 2025 was $1.15M, up from $626,000 in Q2 2024.

• Net loss for the six months ended June 30, 2025 was $15.6M, compared to $1.9M in the prior year period.

• Cash and cash equivalents at June 30, 2025 were $624,000, down from $1.99M at year-end 2024.

• Significant $12.9M fair value adjustment to related party note payable recognized in Q2 2025.

Outlook and guidance

• Management plans to monetize intellectual property and tightly control operating costs to address going concern risks.

• The company is actively seeking partners for commercialization of proprietary technologies and expects the merger with Dr Ashleys Limited to close in Q4 2025.